New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors

The possibility of replacing raltegravir or elvitegravir with dolutegravir in heavily treatment-experienced patients failing on raltegravir/elvitegravir has been evaluated in VIKING trials. All studied patients failed by the most common pathways, Y143, Q148 and N155, and dolutegravir demonstrated ef...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2014-08, Vol.69 (8), p.2118-2122
Hauptverfasser:	Malet, Isabelle, Gimferrer Arriaga, Laura, Artese, Anna, Costa, Giosuè, Parrotta, Lucia, Alcaro, Stefano, Delelis, Olivier, Tmeizeh, Ahmed, Katlama, Christine, Valantin, Marc-Antoine, Ceccherini-Silberstein, Francesca, Calvez, Vincent, Marcelin, Anne-Geneviève
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Substitution Drug resistance Drug Resistance, Viral - genetics Genotype & phenotype Heterocyclic Compounds, 3-Ring - therapeutic use HIV Infections - drug therapy HIV Infections - virology HIV Integrase - genetics HIV Integrase Inhibitors - therapeutic use HIV-1 - drug effects HIV-1 - genetics Humans Hydrogen bonds Inhibitor drugs Multidrug resistant organisms Mutation Protein Binding - genetics Pyrrolidinones - therapeutic use Quinolones - therapeutic use Raltegravir Potassium Treatment Failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!